Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey

作者：Lisa G. Rider, Christine G. Parks, Jesse Wilkerson, Adam Schiffenbauer, Richard K. Kwok, Payam Noroozi Farhadi, Sarvar Nazir, Rebecca Ritter, Emily Sirotich, Kevin Kennedy, Maggie Larché, Mitchell Levine, Sebastian E. Sattui, Jean W. Liew, Carly Harrison, Tarin T Moni, Aubrey K Miller, Michael Putman, Jonathan S. Hausmann, Julia F. Simard, Jeffrey A. Sparks, Frederick W. Miller, the COVID-19 Global Rheumatology Alliance Vaccine Survey Group, Akpabio Akpabio, D. Alpizar-Rodriguez, Françis Berenbaum, Inita Buliņa, Richard Conway, Aman Dev Singh, Eimear Duff, Karen Durrant, Tamer A. Gheita, Catherine Hill, Richard A. Howard, Bimba F. Hoyer, Evelyn Hsieh, Lina El Kibbi, Adam Kilian, Alfred H.J. Kim, David Liew, Chieh Lo, Bruce Miller, S. Mingolla, Michal Nudel, Candace A Palmerlee, Ambrish Singh, Namrata Singh, Manuel F. Ugarte‐Gil, John Wallace, Kristen Young, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro Machado, Philip C. Robinson, Paul Sufka, Zachary S. Wallace, Jinoos Yazdany, Gary Foster, Lehana Thabane, Saskya Angevare, Richard Beesley, Eugenia Yupei Chock, Berk Değirmenci, Christele Felix, Shangyi Jin, Elsa F Mateus, Andrea Peirce, Esra Sarı, Robert Tseng, Leslie Wang, Erick Adrian Zamora · 发表于：Lara D. Veeken · 年份：2022 · DOI：10.1093/rheumatology/keac249 · 被引用次数：71 · 研究领域：Rheumatoid Arthritis Research and Therapies、SARS-CoV-2 and COVID-19 Research、Inflammatory Myopathies and Dermatomyositis

OBJECTIVE: To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD). METHODS: An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression. RESULTS: Flares requiring a change in treatment following COVID-19 vaccination were reported by 4.9% of patients. Compared with rheumatoid arthritis, certain SRD, including systemic lupus erythematosus (OR 1.51, 95% CI 1.03, 2.20), psoriatic arthritis (OR 1.95, 95% CI 1.20, 3.18) and polymyalgia rheumatica (OR 1.94, 95% CI 1.08, 2.48) were associated with higher odds of flare, while idiopathic inflammatory myopathies were associated with lower odds for flare (OR 0.54, 95% CI 0.31-0.96). The Oxford-AstraZeneca vaccine was associated with higher odds of flare relative to the Pfizer-BioNTech vaccine (OR 1.44, 95% CI 1.07, 1.95), as were a prior reaction to a non-COVID-19 vaccine (OR 2.50, 95% CI 1.76, 3.54) and female sex (OR 2.71, 95% CI 1.55, 4.72). CONCLUSIO...